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Abstract
Background: Sex determining region Y (SRY)-related high mobility groupbox 9 (SOX9) is an important
transcription factor required for development, which regulates the expression of target genes in the associated
pathway. The aim of this study was to describe the expression of SOX9 in human non-small cell lung cancer
(NSCLC) and to investigate the association between SOX9 expression and progression of NSCLC.
Methods: SOX9 protein and mRNA expression in normal human pneumonocytes, lung cancer cell lines, and eight
pairs of matched lung cancer tissues and their adjacent normal lung tissues were detected by Western blotting
and real-time reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemistry was used to
determine SOX9 protein expression in 142 cases of histologically characterized NSCLC. Statistical analyses were
applied to test for prognostic and diagnostic associations.
Results: SOX9 in lung cancer cell lines was upregulated at both mRNA and protein levels, and SOX9 mRNA and
protein were also elevated in NSCLC tissues compared with levels in corresponding adjacent non-cancerous lung
tissues. Immunohistochemical analysis demonstrated a high expression of SOX9 in 74/142 (52.1%) paraffin-
embedded archival lung cancer biopsies. Statistical analysis indicated that upregulation of SOX9 was significantly
correlated with the histological stage of NSCLC (P = 0.017) and that patients with a high SOX9 level exhibited a
shorter survival time (P < 0.001). Multivariate analysis illustrated that SOX9 upregulation might be an independent
prognostic indicator for the survival of patients with NSCLC.
Conclusions: This work shows that SOX9 may serve as a novel and prognostic marker for NSCLC, and play a role
during the development and progression of the disease.
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Background
Globally, lung cancer was the most commonly diag-
nosed cancer and the leading cause of cancer death in
males, comprising 13% (1.6 million) of the total cases of
cancer and 18% (1.4 million) of total cancer deaths in
2008 [1]. The main clinical types of lung cancer are
small cell lung cancer(SCLC) and non-small cell lung
cancer (NSCLC). NSCLC represents almost 80% of lung
cancer, which is the leading cause of cancer-related
death in the world. The most common types of NSCLC
are squamous cell lung carcinoma, adenocarcinoma, and
large cell lung cancer. Surgical resection with adjuvant
chemotherapy is the preferred approach for early stage
NSCLC, while patients with advanced NSCLC are
usually treated with chemotherapy or radiation therapy.
Despite advances in treatment, the prognosis is generally
poor. Following complete surgical resection of stage IA
disease, 5-year survival of patients is 67%, but the 5-year
survival rate of individuals with stage IV NSCLC is
below 1% [2]. One reason for such a low survival rate is
that patients do not receive treatment early enough in
disease progression for it to be effective, which is asso-
ciated with the high metastasis character of NSCLC.
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related to various molecular alterations. However, the
cytogenetic and molecular data on various forms of
NSCLC are still being investigated for better under-
standing the disease. The molecular mechanism under-
lying the progression of NSCLC requires further
research, with a view to basing therapy on molecular
signatures within tumors. There is significant clinical
value in early detection and provision of effective inter-
ventions to treat NSCLC.
Sex determining region Y (SRY)-related high mobility
g r o u p( H M G ) - b o x9( S O X 9 )s h a r e s7 0 %a m i n oa c i d
homology to SRY through its HMG box, the domains of
which are involved in the regulation of DNA-dependent
processes, such as transcription and replication [3].
SOX9 function was first identified as a key regulator of
cartilage and male gonad development, with mutations
in SOX9 causing campomelic dysplasia and autosomal
sex reversal [4,5]. Subsequently, it emerged that SOX9
has been found to be upregulated in several tumor
types, such as lung adenocarcinoma, breast carcinoma,
colorectal cancer, and prostate cancer [6-9]. However,
the clinical and functional significance of SOX9 expres-
sion has not been characterized previously in all stages
of NSCLC despite the recently reported correlation
between upregulation of SOX9 and lung adenocarci-
noma, and its association with cancer cell growth [6]. In
the present study, SOX9 expression was characterized in
all stages of NSCLC from early to advanced. This study
found that the expression level of SOX9 was correlated
strongly with the histological stage and the survival time
of NSCLC patients. In addition, the usefulness of SOX9
as a prognostic factor was evaluated by multivariate ana-
lysis. The data revealed that SOX9 could be a lung can-
cer-associated molecule with a prognostic value.
Methods
Cell lines
Primary normal lung epithelial cells (NLEC) were estab-
lished according to a previously report [10]. In brief,
surgical specimens from normal lung were promptly
removed and transported aseptically in Hanks’ solution
(Invitrogen, Carlsbad, CA) with 100 units/ml penicillin,
and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA)
and 5 μg/ml gentamicin (Invitrogen, Carlsbad, CA). The
tissue specimens were incubated with 1.5 units/ml dis-
pase (Roche Molecular Biochemicals) at 4°C overnight,
and the epithelium was dissected away and incubated
with trypsin (Invitrogen, Carlsbad, CA). The reaction
was stopped with soybean trypsin inhibitor (Sigma, Saint
Louis, MI) and centrifuged. The pellet was resuspended
in keratinocyte-SFM medium (KSFM) (Invitrogen, Carls-
bad, CA) supplemented with 40 μg/ml bovine pituitary
extract (Invitrogen, Carlsbad, CA), 1.0 ng/ml EGF
(Invitrogen, Carlsbad, CA), 100 units/ml penicillin, 100
μg/ml streptomycin (Invitrogen, Carlsbad, CA), 5 μg/ml
gentamycin, and 100 units/ml nyastatin (Invitrogen,
Carlsbad, CA). NEEC cells were grown at 37°C and 5%
CO2 with KSFM, with 40 μg/ml bovine pituitary extract,
1.0 ng/ml EGF, 100 units/ml penicillin, and 100 μg/ml
streptomycin. Lung cancer cell lines, including SK-MES-
1, NCI-H460, NCI-H358, NCI-H1650, NCI-H1975,
NCI-H596 and PAa, were provided by American Type
Culture Collection (ATCC) and grown in the Dulbecco’s
Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad,
USA) with 10% fetal bovine serum (Invitrogen) at 37°C
in a 5% CO2 atmosphere.
Patients and tissue specimens
This study was conducted on a total of 142 paraffin-
embedded lung cancer specimens, which were diagnosed
histopathologically at Second Affiliated Hospital of
Guangzhou Medical College from 2006 to 2010. Prior
p a t i e n tc o n s e n ta n da p p r o v a lf r o mt h eI n s t i t u t i o n a l
Research Ethics Committee were obtained to use these
clinical materials for research purposes. Clinical infor-
mation on these samples is described in Table 1. Per-
centage tumor purity in sections adjacent to the regions
used for RNA extraction was estimated during routine
histopathological analysis. Normal lung tissues were
obtained from First Affiliated Hospital of Shenzhen Uni-
versity by collecting donations from individuals who
died in traffic accidents and were confirmed to be free
of any prior pathologically detectable conditions. The
tumors were staged according to the 7
th edition of the
Cancer Stage Manual written by the American Joint
Committee on Cancer (AJCC) [11].
RNA extraction and real-time reverse transcription-
polymerase chain reaction
Total RNA from cultured cells was extracted using the
TRIzol reagent (Invitrogen) and purified using the pure-
link RNA Mini Kit (Invitrogen) according to the manu-
facturer’s instructions. Real-time reverse transcription-
polymerase chain reaction (RT-PCR) was employed to
quantify the change of SOX9 mRNA level in lung cancer
cell lines compared with that in normal human pneumo-
nocytes. Real-time RT-PCR primers and probes for
SOX9 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were designed with the assistance of the Pri-
mer Express version 2.0 software (Applied Biosystems).
Primer sequences
SOX9 forward primer: 5’-CGAAATCAACGA-
GAAACTGGAC-3’, SOX9 reverse primer: 5’-ATTTAG-
CACACTGATCACACG-3’,S O X 9p r o b e5 ’-(FAM)
CCATCATCCTCCACGCTTGCTCTG (TAMRA)-3’,
GAPDH forward primer: 5’-GACTCATGACCA-
CAGTCCATGC-3’, GAPDH reverse primer: 5’-
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5’-(FAM) CATCACTGCCACCCAGAAGACTGTG
(TAMRA)-3’.
Expression data were normalized to the housekeeping
gene GAPDH and calculated as 2-
[(Ct of gene)-( C to f
GAPDH)], where Ct represents the threshold cycle for
each transcript.
Western blotting
Cells were harvested in sampling buffer and boiled for
10 min. The procedure was perfomed similarly to pre-
viously described methods [12]. Protein concentration
was determined with the bicinchoninic acid (BCA) assay
(Pierce, Rockford, USA) according to the manufacturer’s
instructions. Equal amounts of protein were separated
electrophoretically on 10% sodium dodecyl sulfate
(SDS)-polyacrylamide gels andt r a n s f e r r e do n t op o l y v i -
nylidene difluoride membranes (Millipore, Bedford,
USA). The membrane was probed with an anti-SOX9
rabbit antibody (1:2,000 dilution; Millipore) and
incubated with goat anti-rabbit immunoglobulin G
(1:50,000 dilution; Pierce). Expression of SOX9 was
determined with SuperSignal West Pico Chemilumines-
cent Substrate (Thermo, USA) according to the manu-
facturer’s suggested protocol. The membranes were
stripped and reprobed with an anti-actin mouse mono-
clonal antibody (1:2,000 dilution; Millipore) as a loading
control.
Immunohistochemistry (IHC)
Immunohistochemical analysis was performed to study
altered protein expression in 142 human lung cancer tis-
sues. The procedures were carried out in a similar man-
ner to previously described methods [13]. Paraffin-
embedded specimens were cut into 4 μms e c t i o n sa n d
baked at 65°C for 30 minutes. The sections were depar-
affinized with xylenes and rehydrated. Sections were
submerged into ethylenediaminetetraacetic acid anti-
genic retrieval buffer and microwaved for antigenic
retrieval. The sections were treated with 3% hydrogen
peroxide in methanol to quench the endogenous peroxi-
dase activity, followed by incubation in 1% bovine serum
albumin to block non-specific binding. Rabbit anti-
SOX9 (1:50 dilution; Millipore) was incubated with the
sections at 4°C overnight. Primary antibody was replaced
by normal goat serum in the negative controls. After
washing, the tissue sections were treated with biotiny-
lated anti-rabbit secondary antibody (Zymed, San Fran-
cisco, USA) followed by a further incubation with
streptavidin-horseradish peroxidase complex (Zymed).
The tissue sections were immersed in 3-amino-9-ethyl
carbazole and counterstained using 10% Mayer’s hema-
toxylin, dehydrated, and mounted in Crystal Mount
(Sigma). The degree of immunostaining of formalin-
fixed, paraffin-embeddeds e c t i o n sw a sv i e w e da n d
scored separately by two independent investigators, who
were blinded to the histopathological features and
patient details of the samples. Scores were determined
by combining the proportion of positively stained tumor
cells and the intensity of staining. The scores given by
the two independent investigators were averaged for
further comparative evaluation of SOX9 expression. The
proportion of positively stained tumor cells was staged
as follows: 0 (no positive tumor cells), 1 (<10% positive
tumor cells), 2 (10-50% positive tumor cells), and 3
(>50% positive tumor cells). The cells at each intensity
of staining were recorded on a scale of 0 (no staining), 1
(weak staining, light yellow), 2 (moderate staining, yel-
lowish brown), and 3 (strong staining, brown). The
staining index was calculated as follows: staining index
= staining intensity × proportion of positively stained
tumor cells. Using this method of assessment, the
expression of SOX9 in lung cancers was evaluated using
t h es t a i n i n gi n d e x( s c o r e da s0 ,1 ,2 ,3 ,4 ,6 ,o r9 ) .H i g h
Table 1 Clinicopathologic characteristics of studied
patient and expression of SOX9 in NSCLC
No. (%)
Gender
Male 103(72.5)
Female 39(27.5)
Age (years)
≤ 65 89(62.7)
>65 53(37.3)
Pathology
Squamous cell carcinoma 47(33.1)
Adenocarcinoma 68(47.9)
Adenosquamous carcinoma 27(19.0)
NSCLC histology (AJCC grade)
I 32(22.5)
II 25(17.6)
III 58(40.8)
IV 27(19.0)
Survival (n = 89)
Alive 33(37.1)
Dead 56(62.9)
Survial time of low expression
Mean 31.70
Median 28.50
Survival time of high expression
Mean 24.84
Median 24.00
Expression of SOX9
Negative 7(4.9)
Positive 135(95.1)
Low expression 68(47.9)
High expression 74(52.1)
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values based on a measure of heterogeneity with the
log-rank test statistics with respect to overall survival;
an optimal cutoff value was identified. A staining index
score of ≥ 6 was used to define tumors with high
expression and a staining index ≤ 4 was used to define
tumors with low expression of SOX9.
Immunohistochemical staining for protein expression
in tumor and normal tissues was quantitatively analyzed
with the Olympus BX51 image analysis system assisted
with the CellSens Dimension 1.5 Imaging software. The
stained sections were evaluated at × 200 magnification
and 10 representative staining fields per section were
analyzed to verify the mean absorbance, which repre-
sents the strength of staining signals as measured per
positive pixels. The mean absorbance data were analyzed
statistically using t test to compare the average mean
absorbance difference between different groups of tis-
sues; a P < 0.05 was considered significant.
Statistical analysis
All statistical analyses were carried out using the statisti-
cal software package, SPSS, version 17.0 (IBM SPSS,
Chicago, USA). The c
2 test was used to analyze the rela-
tionship between SOX9 expression and the clinicopatho-
logical characteristics. Bivariate correlations between
study variables were calculated by Spearman rank corre-
lation coefficients. Survival curves were plotted with the
Kaplan-Meier method and compared by the log-rank
test. Survival data were evaluated using univariate and
multivariate Cox regression analyses. In all cases, P <
0.05 was considered statistically significant.
Results
Increased expression of SOX9 in NSCLC
Western blotting and real-time PCR analyses were per-
formed to determine the levels of SOX9 protein and
mRNA, respectively, in primary normal lung epithelial
cells (NLEC) and seven NSCLC cell lines: SK-MES-1,
NCI-H460, NCI-H358, NCI-H1650, NCI-H1975, NCI-
H596, and PAa. All tumor cell lines showed significantly
higher levels of SOX9 protein (Figure 1A) and SOX9
mRNA expression (Figure 1B) compared with NLEC,
which showed no or marginal SOX9 expression.
To determine whether the level of SOX9 is associated
with the progression of NSCLC, comparative analysis of
SOX9 expression was conducted on eight pairs of
matched lung cancer tissue and the non-cancerous tis-
sue adjacent to the malignant lesion using Western blot-
ting and real-time RT-PCR analyses. As shown in Figure
2A, the expression of SOX9 protein was upregulated in
all eight human primary NSCLC samples compared
with their paired adjacent non-cancerous tissue. Simi-
larly, the mRNA expression level of SOX9 was also
upregulated in NSCLC malignant lesions compared with
that in the paired adjacent lung tissue (Figure 2B). It
should be noted that the level of SOX9 protein in the
NSCLC cell lines and clinical lung cancer tissues was
paralleled with the mRNA expression level, indicating
the possibility that the increase of SOX9 in NSCLC
might be largely attributable to regulation at the mRNA
level.
Correlation between increased expression of SOX9 and
malignancy of NSCLC
To determine whether the expression level of SOX9
protein is associated with the histological characteristics
of NSCLC, 142 paraffin-embedded, archived NSCLC
clinical specimens, which included 32 cases of stage I,
25 cases of stage II, 58 cases of stage III, and 27 cases of
stage IV lung cancers, were examined by immunohisto-
chemical staining with an antibody against human
S O X 9 .A ss h o w ni nF i g u r e3 A ,S O X 9w a sf o u n dt ob e
upregulated in NSCLC (c and d, stage I NSCLC; e and
f, stage II NSCLC; g and h, stage III NSCLC; and i and
j, stage IV NSCLC) compared with that in the normal
lung tissue (Figure 3). As summarized in Table 1, SOX9
protein was detected in 135 of 142 (95.1%) cases. High
levels of SOX9 were present in areas containing tumor
Figure 1 Expression of SOX9 was elevated in NSCLC cell lines.
A and B. Expression analysis of SOX9 protein and mRNA in normal
human pneumonocyte (NLE) and NSCLC cell lines (SK-MES-1, NCI-
H460, NCI-H358, PAa, NCI-H596, NCI-H1650, NCI-H1975) by Western
blotting (A) and real-time RT-PCR (B). Protein expression levels were
normalized with b-actin mRNA expression levels were normalized
for GAPDH. Bars, SD from three independent experiments.
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trast, SOX9 was barely detectable in normal lung tissue
(Figure 3A and 3B). Quantitative analysis indicated that
the average mean absorbance of SOX9 staining in stage
I-IV tumors was statistically significantly higher than in
normal lung tissue (P < 0.01; Figure 3B).
Expression of SOX9 protein and histological staging of
NSCLC
Immunostaining examination of tumor sections
obtained from 142 patients showed that positive SOX9
expression was found to be correlated strongly with the
clinicopathological stages of the patients’ cancer (P =
0.022), but no significant relationship was found
between age (P =0 . 3 8 2 )o rg e n d e r( P = 0.240), or
pathology (P = 0.312) (Table 2). Spearman correlation
analysis revealed a correlation coefficient of 0.200 (P =
0.017; Table 3) between SOX9 expression level and the
histological grading of NSCLC. Taken together, these
observations support the notion that the progression of
NSCLC is associated with increased SOX9 expression.
Association between SOX9 expression and patient
prognosis
The statistical analysis presented in Table 2 revealed an
inverse correlation between SOX9 level and patient sur-
vival (P = 0.040). Spearman analysis also showed a cor-
relation coefficient of -0.239 (P = 0.024; Table 3)
between SOX9 and patient survival. Log-rank test and
Kaplan-Meier analysis were also applied to evaluate
further the effect of SOX9 expression and histological
staging of lung cancer on survival. The log-rank test
showed that the expression level of SOX9 protein in
NSCLC was correlated significantly with patients’ survi-
val time (P < 0.001), with a correlation coefficient of
-0.262 (Figure 4; Table 4). As shown in Figure 4, the
cumulative 3-year survival rate was 65.9% in the low-
SOX9 expression group (n = 44), and 24.5% in the high-
SOX9 expression group (n = 45). The multivariate survi-
val analysis shown in Table 4 indicated that SOX9
expression level was an independent prognostic factor in
the assessment of patient outcomes.
The prognostic value of SOX9 expression in different
subgroups of NSCLC patients was stratified in relation
to the histological staging. A significant correlation
was found between high SOX9 expression and shorter
overall survival time in AJCC-graded subgroups of
NSCLC. Patients with tumors exhibiting high SOX9
expression had significantly shorter overall survival
than those with low expression of SOX9 in either
stages I + II subgroup (n = 43; P = 0.001, log-rank;
Figure 5A) or stages III + IV subgroup (n = 56; P =
0.020, log-rank; Figure 5B), indicating that SOX9 could
be a valuable prognostic marker for NSCLC patients at
all disease stages.
Discussion
The major finding of our study is that the progression
of human NSCLC is related to upregulation of SOX9
expression. Although, a previous report has described a
correlation between the expression of SOX9 mRNA and
protein levels with lung adenocarcinoma [6], this study
represents the first demonstration that SOX9 mRNA
and protein are upregulated in all stages of human
NSCLC and that this degree of upregulation increases as
NSCLC progresses to advanced stages.
Figure 2 Differential expression of SOX9 in human NSCLC tissues (T) and their paired normal lung tissue (N), each pair obtained from
the same patient. A, Western blotting analysis of SOX9 protein expression in eight paired tumor and normal tissue samples, average tumor/
normal ratios of SOX9 protein expression quantified using the LabWorks software. Expression levels were normalized with b-actin. B, average
tumor/normal ratios of SOX9 expression were quantified by real-time RT-PCR. Expression levels were normalized for GAPDH. Bars, SD from three
independent experiments
Zhou et al. Journal of Experimental & Clinical Cancer Research 2012, 31:18
http://www.jeccr.com/content/31/1/18
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SOX9 and cancer development and progression
[14,15], and the upregulation of SOX9 has been
observed in several types of solid tumors, including
lung adenocarcinoma, breast carcinoma, colorectal
cancer, and prostate cancer [6-9]. In addition, there is
marked inhibition of differentiation, coupled with an
expanded domain of expression of SOX9 protein in
Nmyc overexpressing lung [16]. It has been reported
that the induction of SOX9 expression could be
induced through various mechanisms. Dysregulation of
tissue development pathways can be conducive to can-
cer initiation and progression. As part of a develop-
mental pathway, elevation of SOX9 in prostate
neoplasia promotes tumor cell proliferation [17].
Moreover, as a transcription factor, SOX9 is linked to
the hedgehog pathways and may play a role in the
development of malignant peripheral nerve sheath
tumor in patients [18]. Ling et al. reported that despite
SOX9 levels being high during periods of prenatal
urothelial development in mouse bladders, SOX9 was
diminished and quiescent with maturation after birth,
Figure 3 Immunohistochemical analysis of SOX9 expression in
normal lung tissue and primary NSCLC. A, thin sections of
paraffin-embedded specimens of a total of 2 normal lung tissues
and 142 primary NSCLC specimens including AJCC grade I to IV
NSCLC samples were stained by immunohistochemistry using an
anti-SOX9 antibody. a and b, normal lung tissue; c and d, AJCC
grade I NSCLC; e and f, AJCC grade II NSCLC; g and h, AJCC grade
III NSCLC; i and j, AJCC grade IV. Amplification, 200 (a, c, e, g, and i)
and 400 (b, d, f, h and j). Immunohistochemical analyses were done
two independent times on each of the samples with similar results.
B, statistical quantification of the average mean absorbance of SOX9
staining between normal lung tissues (4 cases) and NSCLC
specimens of different AJCC grades (30 random cases per grade).
Average mean absorbance of SOX9 staining increases as NSCLC
progresses to higher grades. *, P < 0.01.
Table 2 Correlation between the clinicalpathologic
features and expressions of SOX9
Characteristics SOX9 P-value
Low or none High
Gender 0.382
Male
Female
47
21
56
18
Age (years) 0.240
≤ 65
>65
46
22
43
31
Pathology
Squamous cell carcinoma 26 21 0.312
Adenocarcinoma 32 36
Adenosquamous carcinoma 10 17
NSCLC histology (AJCC grade) 0.022
I and II
III and IV
34
34
23
51
Survival (n = 89) 0.040
Alive
Dead
21
23
12
33
Table 3 Spearman correlation analysis between SOX9
and clinical pathologic factors
Variables SOX9
Spearman Correlation P-Value
Gender -0.083 0.325
Age 0.098 0.247
NSCLC histology
(AJCC grade)
0.200 0.017
Survival -0.239 0.024
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urothelial cancer [19]. All these findings suggest that
SOX9 may play important roles in cancer development
and progression, which prompted the authors to ask
whether it is also clinically associated with the progres-
sion of NSCLC. To address this question, studies were
performed to characterize the expression of SOX9 in
NSCLC cell lines and clinical lung cancer tissues. The
data show that upregulation of SOX9 mRNA and pro-
tein is a common and frequent event in both NSCLC
cell lines and human lung cancer tissues. Comparative
analyses of SOX9 mRNA and protein in lung cancer
tissues and their paired adjacent normal tissue have
provided strong support for the identified upregulation
of SOX9 in NSCLC. Moderate to strong cytoplasmic
staining of SOX9 was displayed in tumor cells from
135/142 (95.1%) paraffin-embedded archived NSCLC
biopsy samples in comparison with the adjacent non-
cancerous cells, which expressed little, if any, SOX9.
Further analysis of the relationship between SOX9
staining and the clinicopathological characteristics of
patients showed a significant correlation between SOX9
expression and the histopathological staging of NSCLC.
This revealed that SOX9 levels were higher in advanced
stages of the disease, supporting the hypotheses that
SOX9 may play a role in the progression of NSCLC and
that it could represent a biomarker that identifies sub-
sets of lung-cancer patients with more aggressive dis-
ease. It is of particular note that patients with high
SOX9 expression had shorter survival time, suggesting
the possibility of using SOX9 as a predictor for patient
prognosis and survival.
In a more detailed survival study, univariate and mul-
tivariate analyses demonstrated that high expression of
SOX9 is a predictor of poor prognosis for lung-cancer
patients. It is of note that there is a significant correla-
tion between shorter overall survival times of patients
and high SOX9 expression in both the early histological
stage subgroup (stages I and II) and the late histological
stage subgroup (stages III and IV), suggesting that
SOX9 may be a useful prognostic marker for all stages
of NSCLC.
Conclusions
Although several lines of evidence have suggested that
SOX9 might be involved in cancer development and
progression, only a few studies have linked SOX9 to
Figure 4 Kaplan-Meier curves with univariate analyses (log-
rank) for patients with low SOX9-expressing (bold line) versus
high SOX9-expressing tumors (dotted line). The cumulative 3-
year survival rate was 65.9% in the low SOX9 expression group (n =
44), whereas it was only 24.5% in the high SOX9 expression group
(n = 45).
Table 4 Univariate and multivariate analysis of different prognostic parameters in patients with NSCLC by Cox-
regression analysis
Univariate analysis Multivariate analysis
No. patients P Regression coefficient
(SE)
P Relative risk 95% confidence interval
Age 0.147 0.020(0.014) 0.779 1.004 0.976-1.032
≤ 65 53
>65 36
NSCLC histology (AJCC grade)
I 33 0.016 0.354(0.146) 0.049 1.368 1.001-1.868
II
III 56
IV
SOX9 0.000 0.776(0.199) 0.001 2.004 1.350-2.974
Low 44
High 45
The expression level of SOX9 protein in NSCLC was significantly correlated with patients’ survival time (P < 0.05); the correlation coefficient was -0.262, indicating
that higher levels of SOX9 expression was correlated with shorter survival time.
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Page 7 of 9lung cancer. Knockdown of SOX9 has been found to
decrease the proliferation rate of lung cancer cell lines
and significantly attenuate the tumorigenicity of lung
adenocarcinoma [6]. Despite the above finding, the pre-
cise pathway that SOX9 uses to inhibit the differentia-
tion of NSCLC and promote lung cancer development
and progression remains unclear. Based on the findings
from this and other studies, further investigation is war-
ranted to validate whether SOX9 can be used as a novel
therapeutic target for NSCLC.
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